↓ Skip to main content

Screening for Colorectal Cancer

Overview of attention for article published in JAMA: Journal of the American Medical Association, June 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Citations

dimensions_citation
812 Dimensions

Readers on

mendeley
362 Mendeley
Title
Screening for Colorectal Cancer
Published in
JAMA: Journal of the American Medical Association, June 2016
DOI 10.1001/jama.2016.5989
Pubmed ID
Authors

Kirsten Bibbins-Domingo, David C. Grossman, Susan J. Curry, Karina W. Davidson, John W. Epling, Francisco A. R. García, Matthew W. Gillman, Diane M. Harper, Alex R. Kemper, Alex H. Krist, Ann E. Kurth, C. Seth Landefeld, Carol M. Mangione, Douglas K. Owens, William R. Phillips, Maureen G. Phipps, Michael P. Pignone, Albert L. Siu

Abstract

Colorectal cancer is the second leading cause of cancer death in the United States. In 2016, an estimated 134 000 persons will be diagnosed with the disease, and about 49 000 will die from it. Colorectal cancer is most frequently diagnosed among adults aged 65 to 74 years; the median age at death from colorectal cancer is 68 years. To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for colorectal cancer. The USPSTF reviewed the evidence on the effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 DNA test in reducing the incidence of and mortality from colorectal cancer or all-cause mortality; the harms of these screening tests; and the test performance characteristics of these tests for detecting adenomatous polyps, advanced adenomas based on size, or both, as well as colorectal cancer. The USPSTF also commissioned a comparative modeling study to provide information on optimal starting and stopping ages and screening intervals across the different available screening methods. The USPSTF concludes with high certainty that screening for colorectal cancer in average-risk, asymptomatic adults aged 50 to 75 years is of substantial net benefit. Multiple screening strategies are available to choose from, with different levels of evidence to support their effectiveness, as well as unique advantages and limitations, although there are no empirical data to demonstrate that any of the reviewed strategies provide a greater net benefit. Screening for colorectal cancer is a substantially underused preventive health strategy in the United States. The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years (A recommendation). The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient's overall health and prior screening history (C recommendation).

Twitter Demographics

The data shown below were collected from the profiles of 515 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 362 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 6 2%
United Kingdom 1 <1%
Kenya 1 <1%
Canada 1 <1%
Hong Kong 1 <1%
Unknown 352 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 66 18%
Student > Master 50 14%
Other 39 11%
Student > Bachelor 29 8%
Student > Ph. D. Student 29 8%
Other 86 24%
Unknown 63 17%
Readers by discipline Count As %
Medicine and Dentistry 172 48%
Nursing and Health Professions 25 7%
Biochemistry, Genetics and Molecular Biology 18 5%
Social Sciences 15 4%
Computer Science 6 2%
Other 35 10%
Unknown 91 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 1860. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2020.
All research outputs
#1,914
of 15,936,051 outputs
Outputs from JAMA: Journal of the American Medical Association
#86
of 28,187 outputs
Outputs of similar age
#37
of 267,978 outputs
Outputs of similar age from JAMA: Journal of the American Medical Association
#3
of 425 outputs
Altmetric has tracked 15,936,051 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 28,187 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 60.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 425 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.